Natural Healing Through Pure Resorption™

PRODUCT

ART is a leading innovator in the field of the next generation of fully BioResorbable Scaffolds (BRS) that promote the natural remodeling of an injured artery after vascular angioplasty
ART PBS Scaffold

The ART Pure Bioresorbable Scaffold (PBS) is providing effective scaffolding followed by programmed dismantling at around 3 months to enable positive remodeling and complete resorption within 24 months.

Procedure

The ART PBS is expanded following balloon pre-dilatation of a vascular lesion. After an effective scaffolding period of 3 months, the scaffold dismantles and releases the artery before it completely resorbs.

Clinical Data

The ART PBS has been investigated in the multicenter ARTDIVA trial and shown proven scaffolding properties with only 4.3 % angiographic recoil and good drug free BRS long term performances.

ART’s Unique Proprietary Polymer Provides a Versatile Platform for Vascular Scaffolding

technology

A disruptive new technology for the treatment of coronary and peripheral arterial disease
Core Technology

Unique, proprietary PLA platform technology with tunable dismantling, material preserving transformation processes with precise and secure crimping.

Healthy Healing

Effective scaffolding followed by programmed dismantling at around 3 months to enable positive remodeling and safe complete resorption within 24 months.

In vitro Data

State of the ART in vitro assay development and characterization equipment enhanced strong supportive data for every stage of the bioresorption process.

In vivo Data

Extensive preclinical trial track record with proven safety data from dual GLP animal model investigations with > 250 implantations and up to 36 months follow up.

About

ART is a leading innovator in the field of the next generation of fully BioResorbable Scaffolds (BRS) that promote
the natural remodeling of an injured artery after vascular angioplasty
Bioresorbable Scaffolds are the 4th generation PCI

Key milestones
Pr. Lafont, interventional cardiologist, and Pr. Vert, world leading expert in bioresorbable polymers, meet and decide after initial academic research to found ART.

Pre 2008, ART focuses efforts on the exploration of various bioresorbable PLA formulas and scaffold concepts.

From 2009 to 2011 development of ART’s first generation bioresorbable scaffold ART PBS, for the most clinically, technically and regulatory demanding indication: coronary angioplasty.

Development plans were established in collaboration with world leading independent experts like, Dr Virmani, Dr Popma and Dr Fajadet.

2012 First implantation on human in Toulouse by Dr Fajadet.

2014 ART signs structured buyout agreement with Terumo, validating ART’s next-gen bioresorbable scaffold.

2015 ART receives CE mark approval for its drug free ART PBS device.

  • Machiel van der Leest CEO / director

    Machiel as a seasoned medical device professional and entrepreneur has developed and introduced over 10 class III devices in the European and global interventional coronary and neurovascular market. In his 15+ years career Machiel held executive positions as CTO and CSO at Nycomed Amersham Medical Systems, Cathnet Science and he co-founded Minvasys. His decisive focus on managing innovation combined with his strong track record, have been the driving forces behind ART since 2009.  

    Machiel holds a MSc degree from the Technical University Delft, Netherlands, and he is an inventor of over 20 patents.

  • Sophie Humbert COO

    Sophie is a driven and structured manager and has successfully taken several medical devices from development, through CE marking, to sales. Before joining ART in 2014, with her 13 years experience, Sophie held executive positions as CSO and CEO at medtech start-ups, where she launched innovative devices on the market, expanded sales in Europe and established successful industrial and academic partnerships. Results-oriented, her strong track record is a key to bring ART to success.   

    Sophie holds a PhD in Pharmaceutical Sciences from the University of Geneva, Switzerland.

ClientClientClientClientClientClient

FOUNDERS

Pr. Antoine Lafont
Pr. Lafont is interventional cardiologist at Georges Pompidou Hospital, Professor at Paris Descartes University, and co-founder of EAPCI (ESC). He identified in 1991 the role of arterial remodeling in the healing process post angioplasty during his post-doctoral fellowship at the Cleveland Clinic where he met with Dr. Cornhill, and performed his PhD thesis with Pr. Vert on the selection of polylactic acids for arterial scaffolds after his return in France.
Pr. Michel Vert
Pr. Vert founded the Laboratory of Macromolecular Substances at the INSA Rouen in 1981. In 1991, he created the joint CNRS University Montpelier unit devoted to Polymeric Biomaterials, Biology and Health. Pr. Vert is the author of 330 articles, book chapters and is an inventor on many patents. He cofounded several Med- and Biotech’s. He received awards as “Jungfleish” Grand Prix of the French Academy of Sciences in 2001 and Grand Prix Georges Winter of the European Society for Biomaterials in 2005.
Dr. Frederick Cornhill
Dr. Cornhill is the Co-Director of the Minimally Invasive New Technology (MINT) Program at New York Presbyterian and Weill Cornell Medical Center. Dr. Cornhill was the founding Chairman of the Department of Biomedical Engineering at the Cleveland Clinic and the founding Director of the Institute for Biomedical Engineering at the University of Oxford. Dr. Cornhill founded a number of medical technology companies and served on the board of several medical technology startups.

BOARD

NEWS

Get in touch